- Home
- PCQ vs ITRM Comparison
PCQ vs ITRM Comparison
Compare PCQ & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- ITRM
- Stock Information
- Founded
- PCQ 2001
- ITRM 2015
- Country
- PCQ United States
- ITRM Ireland
- Employees
- PCQ N/A
- ITRM N/A
- Industry
- PCQ Investment Managers
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- PCQ Finance
- ITRM Health Care
- Exchange
- PCQ Nasdaq
- ITRM Nasdaq
- Market Cap
- PCQ 163.2M
- ITRM 40.0M
- IPO Year
- PCQ N/A
- ITRM 2018
- Fundamental
- Price
- PCQ $8.79
- ITRM $0.68
- Analyst Decision
- PCQ
- ITRM Strong Buy
- Analyst Count
- PCQ 0
- ITRM 1
- Target Price
- PCQ N/A
- ITRM $9.00
- AVG Volume (30 Days)
- PCQ 69.6K
- ITRM 625.3K
- Earning Date
- PCQ 01-01-0001
- ITRM 11-13-2025
- Dividend Yield
- PCQ 4.63%
- ITRM N/A
- EPS Growth
- PCQ N/A
- ITRM N/A
- EPS
- PCQ N/A
- ITRM N/A
- Revenue
- PCQ N/A
- ITRM N/A
- Revenue This Year
- PCQ N/A
- ITRM N/A
- Revenue Next Year
- PCQ N/A
- ITRM $482.25
- P/E Ratio
- PCQ N/A
- ITRM N/A
- Revenue Growth
- PCQ N/A
- ITRM N/A
- 52 Week Low
- PCQ $8.19
- ITRM $0.61
- 52 Week High
- PCQ $10.50
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- PCQ 84.55
- ITRM 43.37
- Support Level
- PCQ $8.60
- ITRM $0.64
- Resistance Level
- PCQ $8.70
- ITRM $0.70
- Average True Range (ATR)
- PCQ 0.08
- ITRM 0.05
- MACD
- PCQ 0.05
- ITRM 0.01
- Stochastic Oscillator
- PCQ 91.95
- ITRM 47.57
About PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal and California income tax. The fund makes investments in different sectors such as healthcare, property, education, Natural Gas, and others.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.